Stock comparison
Haemonetics
Teva Pharmaceutical Industries Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
TEVA
Teva Pharmaceutical Industries Limited
Market cap
$39.67B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | TEVA | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 46D | HAE |
| Benjamin Graham | 85A | 60D | HAE |
| Philip Fisher | 60C | 59C | HAE |
| Peter Lynch | 54C | 53C | HAE |
| Joel Greenblatt | 31F | 49D | TEVA |
| Charlie Munger | 54D | 50D | HAE |
| Terry Smith | 55D | 41D | HAE |
Side-by-side metrics
| Metric | HAE | TEVA |
|---|---|---|
| Market cap | $2.98B | $39.67B |
| P/E (TTM) | 24.8x | 25.4x |
| EV/EBIT | 14.1x | 24.8x |
| ROIC (TTM) | 8.37% | 11.49% |
| Gross margin | 55.74% | 51.98% |
| Net margin | 7.29% | 9.03% |
| Revenue CAGR 5y | 7.65% | 2.1% |
| EPS CAGR 5y | 24.62% | 34.13% |
| Debt / Equity | 1.5x | 2.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Revenue CAGR 5y7.65%vs 2.1%+73%
- EV/EBIT14.1xvs 24.8x+43%
- Debt / Equity1.5xvs 2.1x+25%
- Gross margin55.74%vs 51.98%+7%
TEVA leads on
- Market cap$39.67Bvs $2.98B+92%
- EPS CAGR 5y34.13%vs 24.62%+28%
- ROIC (TTM)11.49%vs 8.37%+27%
- Net margin9.03%vs 7.29%+19%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.